News | Artificial Intelligence | May 14, 2021

Algorithms must be tested and continually monitored to assess impact of bias

Artificial intelligence (AI)-driven healthcare has potential to transform medical decision-making and treatment, but AI algorithms must be thoroughly tested and continuously monitored to avoid unintended consequences to patients. In JAMA Network Open, Regenstrief Institute President Peter Embí, M.D., calls for algorithmovigilance (a term he coined for scientific methods and activities relating to evaluation, monitoring, understanding and prevention of adverse effects of algorithms in healthcare) to address

Artificial intelligence (AI)-driven healthcare has potential to transform medical decision-making and treatment, but AI algorithms must be thoroughly tested and continuously monitored to avoid unintended consequences to patients. In JAMA Network Open, Regenstrief Institute President Peter Embí, M.D., calls for algorithmovigilance (a term he coined for scientific methods and activities relating to evaluation, monitoring, understanding and prevention of adverse effects of algorithms in healthcare) to address inherent biases in healthcare algorithms and their deployment. Image courtesy of Regenstrief Institute


May 14, 2021 — Artificial intelligence (AI)-driven healthcare has the potential to transform medical decision-making and treatment, but these algorithms must be thoroughly tested and continuously monitored to avoid unintended consequences to patients.

In a JAMA Network Open Invited Commentary, Regenstrief Institute President and Chief Executive Officer and Indiana University School of Medicine Associate Dean for Informatics and Health Services Research Peter Embí, M.D., M.S., strongly stated the importance of algorithmovigilance to address inherent biases in healthcare algorithms and their deployment. Algorithmovigilance, a term coined by Dr. Embí, can be defined as the scientific methods and activities relating to the evaluation, monitoring, understanding, and prevention of adverse effects of algorithms in healthcare.

"We wouldn't think of treating patients with a new pharmaceutical or device without first ensuring its efficacy and safety," said Embí. "In the same way, we must recognize that algorithms have the potential for both great benefit and harm and, therefore, require study. Also, compared with drugs or devices, algorithms often have additional complexities and variations, such as how they are deployed, who interacts with them, and the clinical workflows where interactions with algorithms take place."

The commentary was in response to a study from IBM scientists evaluating different approaches to debiasing healthcare algorithms developed to predict postpartum depression. Embí stated the study suggests that debiasing methods can help address underlying disparities represented in the data used to develop and deploy the AI approaches. He also said the study demonstrates that the evaluation and monitoring of these algorithms for effectiveness and equity is necessary and even ethically required.

"Algorithmic performance changes as it is deployed with different data, different settings and different human-computer interactions. These factors could turn a beneficial tool into one that causes unintended harm, so these algorithms must continually be evaluated to eliminate the inherent and systemic inequities that exist in our healthcare system," Embí continued. "Therefore, it's imperative that we continue to develop tools and capabilities to enable systematic surveillance and vigilance in the development and use of algorithms in healthcare."

For more information: www.regenstrief.org


Related Content

News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | Radiology Imaging

Jan.26, 2026 — SimonMed Imaging has unveiled an updated brand and the launch of SimonMed Longevity, a new division ...

Time January 27, 2026
arrow
News | Point-of-Care Ultrasound (POCUS)

Jan. 22, 2026 — Qure.ai has received a grant from the Gates Foundation to develop a large open-source multi-modal ...

Time January 23, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
Feature | Cybersecurity | Kyle Hardner

As radiology practices shift toward cloud-based platforms and integrate AI-powered tools, will practices become more ...

Time January 14, 2026
arrow
News | Stroke

Dec. 18, 2025 — Brainomix, a provider of AI-powered imaging biomarkers for stroke and lung fibrosis, has announced ...

Time December 24, 2025
arrow
Subscribe Now